Dawn Waterhouse, director of non-clinicial studies and manager of production and manufacturing with the cancer agency’s investigational drug program, said in an interview that in mice studies, the Irinophore C drug system was “remarkably better in therapeutic effect and less toxic?when compared to Camptosar.

Animals were inoculated with human tumour cells from various types of cancer and then they got Camptosar or Irinophore C for treatment of the tumours they developed.

The cancer agency-developed drug accumulated in the tumours with far greater efficiency and that convinced the scientists that a phase-one trial in humans is now possible. A phase-one trial is meant to evaluate the safety of the drug, not the effectiveness.

Such a trial is not expected to start immediately since researchers need to get more grant funding before proceeding. Work so far on the “proof of principle?concept has been funded with a $250,000 grant from the Canadian Institutes for health research but that federal agency insists that matching funds be obtained from other partners. Scientists are now trying to secure at least another $1.1 million to start the trial in patients with various types of advanced cancers.

What’s unusual about the drug is that it is encapsulated in a fatty coating membrane called liposomes.

The nanoscale technology aspect of the system relates to the fact that the fat molecules are so microscopically tiny (one-fifth the size of a red blood cell), which allows the drug to be infused into patients?veins and then travel to cancer sells where it kills them and also disrupts the vascular system that feeds the growth of tumours.

“In our phase-one trial, we will assess the safety of the drug in 18 patients with advanced solid tumours.

“Patients will be those who have failed standard therapy and their cancer has progressed. These are patients for whom we have nothing more to offer except for investigational drugs,?Waterhouse said.